Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain

In 2020, a highly virulent PRRSV-1 strain emerged in Spain and rapidly spread across the country. The purpose of the present study was to test in a piglet model whether a commercial PRRSV-1 modified live vaccine was able to confer protection against strain R1, a representative of the emerging clade....

ver descrição completa

Detalhes bibliográficos
Autores: Cortey, Martí|||0000-0003-1126-3423, Jiménez Farrerons, Marcel|||0000-0002-6602-7332, Aguirre Molins, Laia|||0000-0003-3257-3965, Sánchez Carvajal, Jose María|||0000-0003-0852-3765, Gómez-Laguna, Jaime|||0000-0002-1787-5642, Domingo Carreño, Ivan|||0009-0001-9927-9069, Clilverd, Hepzibar|||0000-0002-4309-7506, Marcos, M., Menjon, R., Von Berg, S., Mateu de Antonio, Enrique María|||0000-0003-2715-6032
Formato: artículo
Fecha de publicación:2025
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:321016
Acesso em linha:https://ddd.uab.cat/record/321016
https://dx.doi.org/urn:doi:10.1186/s40813-025-00423-y
Access Level:acceso abierto
Palavra-chave:Porcine reproductive and respiratory syndrome virus
Virulence
Vaccine
Pig
id ES_be53386fb72bc47a4dd9fe41ed33fc18
oai_identifier_str oai:ddd.uab.cat:321016
network_acronym_str ES
network_name_str España
repository_id_str
spelling Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strainCortey, Martí|||0000-0003-1126-3423Jiménez Farrerons, Marcel|||0000-0002-6602-7332Aguirre Molins, Laia|||0000-0003-3257-3965Sánchez Carvajal, Jose María|||0000-0003-0852-3765Gómez-Laguna, Jaime|||0000-0002-1787-5642Domingo Carreño, Ivan|||0009-0001-9927-9069Clilverd, Hepzibar|||0000-0002-4309-7506Marcos, M.Menjon, R.Von Berg, S.Mateu de Antonio, Enrique María|||0000-0003-2715-6032Porcine reproductive and respiratory syndrome virusVirulenceVaccinePigIn 2020, a highly virulent PRRSV-1 strain emerged in Spain and rapidly spread across the country. The purpose of the present study was to test in a piglet model whether a commercial PRRSV-1 modified live vaccine was able to confer protection against strain R1, a representative of the emerging clade. For that purpose, two groups of 26 piglets were either vaccinated intradermally or kept as controls; 42 days later, half of the animals in each group were intranasally challenged with the R1 strain. Then, animals were followed to assess the development of clinical signs (until 14 days post-challenge), lung lesions (10- and 35-days post-challenge), weight gains, viremia and nasal shedding and the immune response (anti PRRS virus nucleoprotein antibodies) by ELISA and virus specific-interferon-γ secreting cells by ELISPOT). Challenge of naïve pigs resulted in high fever (up to 41.9 °C), lethargy and severely retarded growth (0.748 kg/day). In contrast, vaccinated/challenged pigs had less fever and for a shorter period, lower clinical scores and a higher average daily weight gain (0.940 kg/day), comparable to the unchallenged animals. At 10 days-post challenge, in naïve animals on average 49.1% of the lung was pneumonic (range 8-81%) while in vaccinated animals the average was 15.7% (4-41%). Duration of viremia was reduced in vaccinated animals and after 14 days post-challenge, most were negative by RT-qPCR. In contrast, 50% of the naïve/challenged pigs remained viremic at 35 days post-challenge. Vaccination induced rapid seroconversion and challenge of naïve animals resulted in 100% of ELISA-positive pigs by day 14 post-challenge. Regarding the development of IFN-γ responses, for vaccinated animals the frequencies increased until day 35 post-vaccination. After challenge, in vaccinated pigs, the peak of the R1-specific IFN-γ response was reached at 14 days and then the viremia ceased, although nasal shedding persisted in some vaccinated animals. In the present trial, vaccination resulted in improved clinical course, better weight gain and reduced viremia. At the peak of the infection, lung lesions were reduced in most animals although some individuals still had extensive pneumonia. In summary, vaccination was shown to provide partial but significant protection against the highly virulent R1 strain. The online version contains supplementary material available at 10.1186/s40813-025-00423-y. 22025-01-0120252025-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/321016https://dx.doi.org/urn:doi:10.1186/s40813-025-00423-yreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3210162026-06-06T12:50:31Z
dc.title.none.fl_str_mv Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
title Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
spellingShingle Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
Cortey, Martí|||0000-0003-1126-3423
Porcine reproductive and respiratory syndrome virus
Virulence
Vaccine
Pig
title_short Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
title_full Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
title_fullStr Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
title_full_unstemmed Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
title_sort Experimental efficacy of vaccination of weaned piglets with a modified-live commercial PRRS virus vaccine against the challenge with a Spanish highly virulent PRRSV-1 strain
dc.creator.none.fl_str_mv Cortey, Martí|||0000-0003-1126-3423
Jiménez Farrerons, Marcel|||0000-0002-6602-7332
Aguirre Molins, Laia|||0000-0003-3257-3965
Sánchez Carvajal, Jose María|||0000-0003-0852-3765
Gómez-Laguna, Jaime|||0000-0002-1787-5642
Domingo Carreño, Ivan|||0009-0001-9927-9069
Clilverd, Hepzibar|||0000-0002-4309-7506
Marcos, M.
Menjon, R.
Von Berg, S.
Mateu de Antonio, Enrique María|||0000-0003-2715-6032
author Cortey, Martí|||0000-0003-1126-3423
author_facet Cortey, Martí|||0000-0003-1126-3423
Jiménez Farrerons, Marcel|||0000-0002-6602-7332
Aguirre Molins, Laia|||0000-0003-3257-3965
Sánchez Carvajal, Jose María|||0000-0003-0852-3765
Gómez-Laguna, Jaime|||0000-0002-1787-5642
Domingo Carreño, Ivan|||0009-0001-9927-9069
Clilverd, Hepzibar|||0000-0002-4309-7506
Marcos, M.
Menjon, R.
Von Berg, S.
Mateu de Antonio, Enrique María|||0000-0003-2715-6032
author_role author
author2 Jiménez Farrerons, Marcel|||0000-0002-6602-7332
Aguirre Molins, Laia|||0000-0003-3257-3965
Sánchez Carvajal, Jose María|||0000-0003-0852-3765
Gómez-Laguna, Jaime|||0000-0002-1787-5642
Domingo Carreño, Ivan|||0009-0001-9927-9069
Clilverd, Hepzibar|||0000-0002-4309-7506
Marcos, M.
Menjon, R.
Von Berg, S.
Mateu de Antonio, Enrique María|||0000-0003-2715-6032
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Porcine reproductive and respiratory syndrome virus
Virulence
Vaccine
Pig
topic Porcine reproductive and respiratory syndrome virus
Virulence
Vaccine
Pig
description In 2020, a highly virulent PRRSV-1 strain emerged in Spain and rapidly spread across the country. The purpose of the present study was to test in a piglet model whether a commercial PRRSV-1 modified live vaccine was able to confer protection against strain R1, a representative of the emerging clade. For that purpose, two groups of 26 piglets were either vaccinated intradermally or kept as controls; 42 days later, half of the animals in each group were intranasally challenged with the R1 strain. Then, animals were followed to assess the development of clinical signs (until 14 days post-challenge), lung lesions (10- and 35-days post-challenge), weight gains, viremia and nasal shedding and the immune response (anti PRRS virus nucleoprotein antibodies) by ELISA and virus specific-interferon-γ secreting cells by ELISPOT). Challenge of naïve pigs resulted in high fever (up to 41.9 °C), lethargy and severely retarded growth (0.748 kg/day). In contrast, vaccinated/challenged pigs had less fever and for a shorter period, lower clinical scores and a higher average daily weight gain (0.940 kg/day), comparable to the unchallenged animals. At 10 days-post challenge, in naïve animals on average 49.1% of the lung was pneumonic (range 8-81%) while in vaccinated animals the average was 15.7% (4-41%). Duration of viremia was reduced in vaccinated animals and after 14 days post-challenge, most were negative by RT-qPCR. In contrast, 50% of the naïve/challenged pigs remained viremic at 35 days post-challenge. Vaccination induced rapid seroconversion and challenge of naïve animals resulted in 100% of ELISA-positive pigs by day 14 post-challenge. Regarding the development of IFN-γ responses, for vaccinated animals the frequencies increased until day 35 post-vaccination. After challenge, in vaccinated pigs, the peak of the R1-specific IFN-γ response was reached at 14 days and then the viremia ceased, although nasal shedding persisted in some vaccinated animals. In the present trial, vaccination resulted in improved clinical course, better weight gain and reduced viremia. At the peak of the infection, lung lesions were reduced in most animals although some individuals still had extensive pneumonia. In summary, vaccination was shown to provide partial but significant protection against the highly virulent R1 strain. The online version contains supplementary material available at 10.1186/s40813-025-00423-y.
publishDate 2025
dc.date.none.fl_str_mv 2
2025-01-01
2025
2025-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/321016
https://dx.doi.org/urn:doi:10.1186/s40813-025-00423-y
url https://ddd.uab.cat/record/321016
https://dx.doi.org/urn:doi:10.1186/s40813-025-00423-y
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418277021679616
score 15,812429